About Structure Therapeutics
Structure Therapeutics is a company based in San Francisco (United States) founded in 2017. Structure Therapeutics has raised $233 million across 3 funding rounds from investors including WuXi AppTec, Citadel and Janus Henderson Investors. The company has 163 employees. Structure Therapeutics operates in a competitive market with competitors including Sana Biotechnology, Semma Therapeutics, Adocia, Altimmune and Rezolute, among others.
- Headquarter San Francisco, United States
- Employees 163
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website structuretx.com
- Social LinkedIn X
- Legal Name Structure Therapeutics, Inc. Sponsored Adr
- Net Profit-$141.58 M (USD)-15.49as on Dec 31, 2025
- EBITDA-$283.67 M (USD)-82.18as on Dec 31, 2025
- Total Equity Funding$233M (USD)
in 3 rounds
- Latest Funding Round$33M (USD), Series B
Aug 2022
- InvestorsWuXi AppTec
& 18 more
- Employee Count163
Funding Insights of Structure Therapeutics
Structure Therapeutics has successfully raised a total of $233M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $33 million completed in August 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $233M
- Total Rounds 3
- Last Round Series B — $33M
- First Round $100M
(Oct 2021)
- Investors Count 19
All 3 funding rounds of Structure Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2022 | $33M | Series B | – | – | |
| Oct 2021 | $100M | Series B | – | BVF Partners | |
| Oct 2021 | $100M | Series D | – | – |
19 investors in total: 19 institutional.
Investors in Structure Therapeutics
Structure Therapeutics has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include WuXi AppTec, Citadel and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Deep Track Capital is engaged in biotechnology investment activities. | – | deeptrackcapital.com | Greenwich, United States | |
US private equity investments are managed by BVF Partners. | – | bvflp.com | San Francisco, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | – | casdincapital.com | - | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
- | – | tcgcrossover.com | - | |
Private equity investments in China are managed by TMCP. | – | terramagnumcap.com | Chaoyang, China | |
Venture capital investment and global platform support for startups. | 2008 | eightroads.com | London, United Kingdom | |
Investments in life sciences, technology, healthtech, and crypto sectors from global locations. | – | fprimecapital.com | - | |
Venture capital investments are directed toward multiple sectors. | 2006 | qimingvc.com | Shanghai, China | |
TF Capital is engaged in biotech investment and strategic support. | – | tfcapital.net | Shanghai, China |
Investor details for Structure Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Structure Therapeutics
25 people are tracked at Structure Therapeutics (16 in leadership, 9 in team); the tracked headcount is 163.
| Name | Role | Group |
|---|---|---|
Xinglong Jiang | Senior Vice President | Leadership |
Raymond Stevens | Chief Executive Officer | Leadership |
Xichen Lin | Chief Scientific Officer | Leadership |
Xianqiang Song | Senior Director Of Structural Biology | Leadership |
Blai Coll | Chief Medical Officer | Leadership |
Tony Peng | Senior VP, Legal | Leadership |
Fang Zhang | Executive Vice President, Biology | Leadership |
Michael Pelayo | Director, Clinical Operations | Leadership |
Aline Barth | Vice President, Head Of Clinical Pharmacology And Pharmacometrics | Leadership |
Karen S. Wright | Senior Vice President, Finance | Leadership |
Lawrence Kwong, CPA | Executive Director Of SEC Reporting And Technical Accounting | Leadership |
Chelsea Olsen | Executive Director Regulatory Medical Writing | Leadership |
Yingli Ma | Chief Technology Officer | Leadership |
Jun Y. | Chief Financial Officer | Leadership |
Robert Gatmaitan | Senior Vice President, People | Leadership |
Crystal Cotter Anglen | Executive Director, Medical Affairs and Advocacy Engagement | Leadership |
Veronica Liu | Senior Operation Manager | Team |
Marc Navre | Senior Advisor | Team |
Qinxuan(Steven) Wang | Senior Scientist | Team |
Amber Xia | Sr. Manager, Operations | Team |
5 more people are available in the full profile.
Complete people profiles for Structure Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Structure Therapeutics
Structure Therapeutics is a publicly listed company on the NASDAQ with ticker symbol GPCR in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date03 Feb 2023
- Listed onNASDAQ: GPCR
- Listed entityStructure Therapeutics, Inc. Sponsored ADR
- Exchange sectorHealth technology
- ISINUS86366E1064
- Share price$25.67 (-3.79% on the day) · 2026-10-08
- Market capitalisation$1.83B
- EPS (diluted, trailing year)$-3.08
- Volume (last session)939,741
Financials of Structure Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -$141.6M | -$283.7M |
| 2024 | – | -$122.6M | -$155.7M |
| 2023 | – | -$89.5M | -$101.7M |
| 2022 | – | -$51.3M | -$51.9M |
| 2021 | – | -$40.1M | -$37.5M |
Detailed financial statements for Structure Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Structure Therapeutics
4 dated milestones of Structure Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Structure Therapeutics is founded.
- Funding First funding round of $100.0M.
- Funding Latest funding round, Series B, of $33.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Structure Therapeutics
Structure Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Semma Therapeutics, Adocia, Altimmune and Rezolute, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| semma-tx.com | 2015 | Cambridge, United States | $158M | 58 | Provider of bio-artificial pancreas for Type 1 Diabetes treatment | |
| adocia.com | 2005 | Lyon, France | $26M | – | Therapeutics for diabetes and obesity treatment are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. | |
| rezolutebio.com | 2012 | Denver, United States | – | 51 | Therapies for metabolic and orphan diseases are developed by Rezolute. | |
| carmot.us | 2008 | Berkeley, United States | $385.52M | – | Disease-modifying therapies for metabolic diseases are developed. | |
| cellinobio.com | 2017 | Cambridge, United States | $125M | 63 | Developer of autologous cell therapies | |
| bioagelabs.com | 2015 | Vallejo, United States | $293.9M | 43 | Bioinformatics platform is provided for biomarkers and drug discovery. | |
| atyrpharma.com | 2005 | San Diego, United States | $171.52M | 65 | Protein biologics are developed for treating rare diseases. |
Detailed competitors of Structure Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Structure Therapeutics
The website of Structure Therapeutics (structuretx.com) receives about 23.1K visits a month and ranks #1,169,135 among all websites worldwide, #1,463 in Biotechnology and Pharmaceuticals.
- Monthly visits23.1K
▲ 10.5% vs previous month
- Unique visitors10.1K
per month
- Global rank#1,169,135
among all websites
- Category rank#1,463
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit2.3
- Average visit1 min 37 sec
- DevicesDesktop 46% · Mobile 54%
Latest news on Structure Therapeutics
Complete news archive for Structure Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Structure Therapeutics
10 companies that operate in the same segment as Structure Therapeutics (Obesity), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Therapeutics for diabetes and obesity treatment are developed. | 2005 | Lyon, Auvergne-rhone-alpes, France | USD 26 M | USD 1.74 M | 77 | |
Bioinformatics platform is provided for biomarkers and drug discovery. | 2015 | Vallejo, California, United States | USD 293.9 M | USD 8.99 M | 64 | |
Disease-modifying therapies for metabolic diseases are developed. | 2008 | Berkeley, California, United States | USD 385.52 M | – | – | |
Small molecule therapeutics for obesity and metabolic disorders are developed. | 2017 | San Diego, California, United States | USD 138 M | – | 22 | |
Therapeutic devices for obesity and GI disorders are developed. | 2005 | Austin, Texas, United States | USD 80.36 M | USD 76.86 M | 132 | |
Nonsurgical endoscopic devices for GI tract anastomoses are developed. | 2012 | West Bridgewater, Massachusetts, United States | USD 91.98 M | – | 15 | |
Biopharmaceuticals for obesity and metabolic diseases are developed. | 2022 | New York, New York, United States | USD 505 M | – | 81 | |
Technology for oral delivery of large drug molecules is developed. | 2012 | San Jose, California, United States | USD 234.14 M | USD 1.63 M | 105 | |
Protein-based therapies for sarcopenia and muscle regeneration are developed. | 2017 | San Mateo, California, United States | USD 75.81 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Structure Therapeutics
Structure Therapeutics was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Structure Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Structure Therapeutics is a funded company, having raised a total of $233M across 3 funding rounds to date. The company's 1st funding round was a Series D of $100M, raised on Oct 2021.
Structure Therapeutics has 163 employees.
Structure Therapeutics is engaged in the development of therapeutic solutions. The specific sectors or focus areas are not detailed on the site. Information regarding their pipeline or specific approaches remains undisclosed in the provided content. The company appears to operate within the healthcare or biotechnology field, though further details are not available.
Structure Therapeutics's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Yes, Structure Therapeutics is publicly traded on NASDAQ under the ticker symbol GPCR.
Structure Therapeutics has 19 investors. Key investors include WuXi AppTec, Citadel, Janus Henderson Investors, Piper Sandler, and Qiming Venture Partners.
Structure Therapeutics operates through Structure Therapeutics Inc..